Asthma Sprays Primatene Mist, Asthmanefrin Await FDA Decisions
This article was originally published in The Pink Sheet Daily
Executive Summary
Armstrong Pharmaceuticals waits to learn the fate of its recently submitted NDA for reformulated Primatene Mist, and Nephron Pharmaceuticals contests FDA’s September warning that its Asthmanefrin is an unapproved drug.